Abstract| Volume 51, SUPPLEMENT 1, S9-S10, March 2015

Download started.


ITOC2 – 026. A new fusion receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy

      This paper is only available as a PDF. To read, Please Download here.


      Recent evidence suggests that the co-inhibitory PD-1-PD-L1 axis plays a major role in adoptive T cell therapy failure. We hypothesised that a new fusion receptor reverting PD-1-mediated inhibition into CD28-costimulation may brake peripheral tolerance.


      Different PD-1-CD28 fusion receptor constructs were created and retrovirally transduced into primary, ovalbumine specific CD8+ T cells (OT-1). Cytokine release, proliferation, cytotoxicity and tumour recognition were analysed in vitro. Anti-tumour efficacy and mode of action were investigated in mice bearing subcutaneous Panc-OVA tumours.


      Transduction of the PD-1-CD28 receptor constructs mediated enhanced cytokine-release, pronounced T cell proliferation and T cell-induced lysis of target tumour cells upon PD-L1 engagement. The PD-1-CD28 receptor function was dependent on two of the CD28-signalling motifs and interferon (IFN)-γ release. Treatment of mice with established Panc-OVA tumours with fusion receptor-transduced OT-1 T cells mediated complete tumour regression in 83% of mice. Mice rejecting the tumour were protected upon subsequent rechallenge with either ovalbumin positive or negative tumours, indicative of a memory response and epitope spreading. Treatment efficacy was associated with accumulation of IFN-γ producing T cells in the tumours.


      Transduction of T cells with this new receptor has the potential of braking the PD-1-PD-L1 immunosuppressive axis in ACT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect